Validation of cytogenetic-based risk stratification in primary myelofibrosis

Blood

Volumn 115, Issue 13, 2010, Pages 2719-2720

  Rumi, Elisa ^a   Passamonti, Francesco ^a   Bernasconi, Paolo ^a   Arcaini, Luca ^a   Pietra, Daniela ^a   Elena, Chiara ^a   Boveri, Emanuela ^a   Pascutto, Cristiana ^a   Cazzola, Mario ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

BONE MARROW CULTURE; CHROMOSOME 13; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME ANALYSIS; HUMAN; KARYOTYPE; LETTER; MYELOFIBROSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 77951015383     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-258988     Document Type: Letter

References (8)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
2. Reilly JT. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia. 2008;22(10):1818-1827.
3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
4. Hidaka T, Shide K, Shimoda H, et al. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol. 2009;83(4):328-333.
5. Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009;113(18):4171-4178.
6. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-5593.
7. Hussein K, Pardanani AD, van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115(3):496-499.
8. Bernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol. 1994;46(4):270-277.